BCAX chief legal officer awarded 90,000 options

Bicara Therapeutics Inc. reported that its Chief Legal Officer, Lara Meisner, received a grant of stock options on February 2, 2026.

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reported that its Chief Legal Officer, Lara Meisner, received a grant of stock options on February 2, 2026. The award covers 90,000 options to buy common stock at an exercise price of $16.76 per share.

The options vest in sixteen equal quarterly installments following February 2, 2026, and each vesting event requires Meisner’s continued service with the company. After this grant, she directly holds 90,000 derivative securities in the form of stock options.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Meisner Lara

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BCAX disclose about Lara Meisner’s recent equity award?

Bicara Therapeutics disclosed that Chief Legal Officer Lara Meisner received stock options covering 90,000 shares of common stock at a $16.76 exercise price. The grant was made on February 2, 2026, and represents a new equity-based compensation award for the executive.

What are the key terms of Lara Meisner’s 90,000 BCAX stock options?

The 90,000 stock options allow Lara Meisner to purchase Bicara Therapeutics common stock at $16.76 per share. The options were granted February 2, 2026, vest over time, and expire on February 2, 2036, providing a long-term incentive tied to the company’s share performance.

How do Lara Meisner’s BCAX options vest over time?

The options vest in sixteen equal quarterly installments after February 2, 2026. Each quarter, one-sixteenth of the 90,000 options becomes exercisable, but only if Lara Meisner continues serving the company on each applicable vesting date, reinforcing long-term retention and alignment.

How many BCAX derivative securities does Lara Meisner own after this grant?

Following this grant, Lara Meisner beneficially owns 90,000 derivative securities in the form of stock options. These options give her the right to buy Bicara Therapeutics common shares at $16.76, subject to the quarterly vesting schedule and her continued service conditions.

Does the BCAX filing show whether the options are held directly or indirectly?

The filing indicates that Lara Meisner holds the 90,000 stock options directly rather than through an intermediary entity. No indirect ownership structure or related entity is listed for this award, so the reported beneficial ownership is in her direct capacity as an officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meisner Lara

(Last) (First) (Middle)

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.76	02/02/2026		A		90,000		(1)	02/02/2036	Common Stock	90,000	$0	90,000	D

Explanation of Responses:

1. The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.